Brain Cell Reservoirs of Latent Virus in Presymptomatic HIV-Infected Individuals

Katherine A. Thompson,* Catherine L. Cherry,† Jeanne E. Bell,‡ and Catriona A. McLean*

From the Pathology Research Laboratory,* Anatomical Pathology Unit and the Centre for Virology,† Burnet Institute, Infectious Diseases Unit, The Alfred Hospital, Department of Medicine, Monash University, Melbourne, Australia; and the Neuropathology Unit,‡ University of Edinburgh, Western General Hospital, Edinburgh, United Kingdom

We detected HIV-1 DNA in pure populations of perivascular macrophages, parenchymal microglia, and astrocytes, isolated using laser microdissection from brain tissue of five untreated individuals who died in the presymptomatic stage of infection from non-HIV causes. HIV-1 DNA was detected in the three cell populations, most consistently in perivascular macrophages, without evidence of productive infection. The percentage of PCR reactions detecting HIV-1 DNA in perivascular macrophages correlated inversely with peripheral blood CD4 counts. These findings demonstrate that brain cell reservoirs of latent HIV-1 exist before pathological HIV encephalitis (HIVE) and suggest that perivascular macrophage trafficking of latent virus into the brain increases with immunosuppression. (Am J Pathol 2011, 179:1623–1629; DOI: 10.1016/j.ajpath.2011.06.039)

Materials and Methods

Brain Pathology

Autopsy brain tissue blocks were obtained from the Medical Research Council HIV Tissue Resource (Edinburgh) and were examined according to guidelines endorsed by the Alfred Hospital Human Ethics committee (HREC #81/07). Five individuals with untreated, established HIV-1 infection who died from HIV-unrelated causes were examined. They had no evidence of HIVE, nor of any other HIV-related neuropathology at autopsy. There was no evidence of any AIDS-defining infection, malignancy, or neurological disease. These individuals were therefore considered to be presymptomatic, with a spectrum of immunodeficiency. Brain tissue from two HIVE and two HIV-negative individuals were used as positive and negative controls, respectively. HIVE was diagnosed pathologically by productive infection of HIV-1 (as evidenced by p24 expression) of perivascular macrophages with or without giant cells with evident microglia activation and/or microglial nodules. Brains were routinely fixed, sectioned, and embedded. Using clean microtome blades, sections (5 μm thick) from the occipital cortex were cut, placed onto charged glass slides, and air-dried overnight before immunohistochemical staining.
Routine H&E staining was performed. A 1:50 dilution of a glial fibrillary acidic protein (GFAP) antibody (Zymed Laboratories, South San Francisco, CA) was used to detect astrocytes. A 1:200 dilution of a CD68 antibody (DakoCytomation, Glostrup, Denmark) was used to detect cells of macrophage lineage. Perivascular macrophages and parenchymal microglia were distinguishable by shape and location. A 1:40 dilution of p24 antibody (DakoCytomation) was used to detect HIV-1 protein. All antibodies were used with the avidin-biotin complex method and a diaminobenzidine hydrogen peroxide product as the colorimetric substrate.

In situ proximity ligation assay (Duolink II; Olink Bioscience, Uppsala, Sweden) was also performed for single HIV-1 protein recognition using a 1:40 dilution of p24 antibody (DakoCytomation), according to the manufacturer’s protocol. Tissue sections were assessed by a neuropathologist (C.A.M.) and with Image-Pro Plus 6.0 image analysis software (MediaCybernetics, Bethesda, MD) for immunopositive cells, as described previously.2

Laser Microdissection

Perivascular macrophages, parenchymal microglia, and astrocytes within the white matter from the occipital region of the cerebral cortex were identified as described above and were laser dissected (P.A.L.M. Microlaser Technologies, Oberkochen/Bernried, Germany) from uncovered IHC stained sections on slides and collected as pure cell populations for subsequent analysis. The occipital region provided a representative view of the immune reaction to HIV-1 in the brain.2 At least 200 cells spanning the entire tissue section were collected from each of the three cell populations, in duplicate from each individual.3,4 Neurons were microdissected from adjacent cortical regions to provide internal negative controls, as described previously.3 Genomic DNA was extracted using the Arcturus PicoPure DNA extraction kit (Applied Biosystems, Foster City, CA) according to the manufacturer’s protocol.

Amplification and DNA Sequence Analysis of HIV-1 GAG

HIV-1 gag sequences were amplified from genomic DNA prepared from laser dissected, captured cell populations. KAPA2G robust hot start DNA polymerase (Kapa Biosystems, Boston, MA) was used to generate a 119-nucleotide (nt) gag fragment in a highly sensitive triple-nested PCR strategy using 40 cycles per round, as described previously.3,5 Primers used were designed against a highly conserved gag region from the HIV-1 clade B consensus sequence. The nucleotide (nt) numbers represent their position relative to the HIV-1 NL4.3 strain: round 1: forward 5’-AGAAGAGCGGGAGGTGAC-3’ nt 1476-1496; reverse 5’-GGGACCGAGGTTTGGCT-3’ nt 1761-1749. Round 2: forward 5’-GCCCTAGAGAAATATGTTGAG-3’ nt 1514–1536; reverse 5’-GAAGTTAGGCTCGTCTTCTTAG-3’ nt 1718-1699. Round 3: forward 5’-TCCACCTATCCAGTAG-
The sensitivity of the triple-nested PCR was determined using a plasmid-containing HIV DNA of known concentration as a template in the triple-nested PCR. The cell populations were collected in duplicate, and the triple-nested PCR was performed on each cell population at least 10 times to determine the frequency of detection. Integrity of DNA was established by performing a similar highly sensitive PCR analysis of cellular GAPDH levels, as described previously. PCR products were sequenced at the Applied Genetic Diagnostics laboratory, Melbourne University (Parkville, Australia), and were aligned against the clade B consensus sequence using DNAMAN 6.0 software (Lynnon, Pointe-Claire, QC, Canada).

### Statistical Analysis

Quantitative data were analyzed using nonparametric tests (Mann-Whitney U-test, Spearman rank correlation) in the Stata 10.1 software package (StataCorp, College Station, TX).

### Results

Clinical details are summarized in Table 1. Neuropathological analysis detected microglial and astrocytic reactivity in the absence of HIV-1 p24 protein in brain tissue from the five cases (Figure 1). Image analysis confirmed increased microglia and astrocyte activation within cases, compared with HIV-1 negative controls ($P = 0.05$).

<table>
<thead>
<tr>
<th>Detection of HIV-1 gag DNA [n/N (% detection rate)$^1$]</th>
<th>Cell count$^2$ (no.)</th>
<th>IHC staining$^3$ (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>PVM Micro Astro PVM Micro Astro PVM Micro Astro</td>
<td></td>
<td></td>
</tr>
<tr>
<td>3/11 (27) 1/11 (9) 2/18 (11)</td>
<td>7.40 29.80 9.80</td>
<td>0.143167 0.814018</td>
</tr>
<tr>
<td>4/12 (33) 1/12 (8) 4/24 (17)</td>
<td>7.00 24.80 9.20</td>
<td>0.118800 0.742597</td>
</tr>
<tr>
<td>30 9 14</td>
<td>7.20 27.30 9.50*</td>
<td>0.130984 0.778638</td>
</tr>
<tr>
<td>4/15 (27) 1/10 (10) 1/11 (9)</td>
<td>2.70 9.90 7.20</td>
<td>0.012492 0.593083</td>
</tr>
<tr>
<td>2/10 (20) 2/18 (11) 1/10 (10)</td>
<td>1.50 18.10 4.60</td>
<td>0.012518 0.62532</td>
</tr>
<tr>
<td>2/10 (20) 0/18 (0) 4/29 (14)</td>
<td>0.40 8.90 4.20</td>
<td>0.012617 0.116776</td>
</tr>
<tr>
<td>2/20 (10) 2/20 (10) 5/22 (23)</td>
<td>2.90 9.80 1.80</td>
<td>0.026765 0.257186</td>
</tr>
<tr>
<td>1/12 (8) 0/16 (38) 0/13 (0)</td>
<td>3.10 10.40 3.20</td>
<td>0.082078 0.410621</td>
</tr>
<tr>
<td>17 14 11</td>
<td>2.12 11.42l 4.2</td>
<td>0.029294 0.327968</td>
</tr>
<tr>
<td>0/10 (0) 0/10 (0) 0/11 (0)</td>
<td>0.70 4.70 3.10</td>
<td>0.002492 0.056377</td>
</tr>
<tr>
<td>0/10 (0) 0/10 (0) 0/11 (0)</td>
<td>0.40 3.20 2.20</td>
<td>0.004189 0.034862</td>
</tr>
<tr>
<td>0 0 0</td>
<td>0.55 3.95 2.65</td>
<td>0.003341 0.045620</td>
</tr>
</tbody>
</table>

HIV Reservoirs in Brain Cells 1625
AJP October 2011, Vol. 179, No. 4

Table 1. Continued

Activation of all cell types within HIVE was increased, compared with the cases and HIV-1-negative groups ($P = 0.05$) (Table 1). Triple-nested PCR was used to determine the presence of HIV-1 gag DNA within genomic DNA extracted from perivascular macrophages, parenchymal microglia, and astrocytes. The sensitivity of the triple-nested PCR was determined to be $\geq 1$ copies of HIV-1 gag DNA per reaction. The gag region was successfully amplified from perivascular macrophages for all five cases (Table 1 and Figure 2A). The gag region was successfully amplified from astrocytes in four of the five cases (not from subject code no. 240), and from parenchymal microglial cells in four of the five cases (not from subject code no. 305). The gag region was successfully amplified in all cell populations in both HIVE individuals and was detected in a greater proportion of perivascular macrophages compared with presymptomatic individuals. HIV-1 gag DNA was not detected in cell populations from HIV-1-negative controls or cortical neurons from HIV-1-infected individuals. Sequence analysis confirmed HIV-1 gag DNA fragments were amplified from the cases specified. Mean percentage interpatient sequence variation in the gag gene is 5%, and the degree of sequence variation in gag correlates with the length of HIV-1 infection. Our sequence analysis in a short segment of the HIV-1 gag gene showed a mean variation from the clade B consensus sequence of 6% in the two HIV encephalitic individuals and 3% in the HIV presymptomatic cases, reflecting expected variation between patients. Resulting amino acid sequences were aligned against the HIV-1 gag consensus sequence (Figure 2C).
The frequency with which HIV-1 gag DNA was detected by triple-nested PCR in the perivascular macrophages of HIV-1-positive individuals correlated inversely with the peripheral blood CD4 count (Spearman correlation, $r = -0.93$, $P = 0.003$) (Figure 2B).

**Discussion**

The optimal time to begin combination antiretroviral therapy for chronically infected individuals remains to be determined, although current guidelines recommend starting treatment when CD4 cell counts are less than 350 cells/mL. Preventing the development of HIV requires an understanding of how, where, and when the virus accesses the brain and whether a latent viral reservoir exists within the CNS, sequestered from systemic immune surveillance. If such a reservoir is present, current therapeutics may be unable to eliminate an established CNS reservoir, allowing later reactivation. Key research priorities for HIV-1 eradication include identifying anatomical and cellular reservoirs, to allow the development of targeted strategies that eliminate virus from these sites.

PCR studies have confirmed low levels of HIV-1 DNA in homogenized brain samples of some presymptomatic subjects without evidence of productive HIV infection.
Nonetheless, there is still no conclusive evidence as to which brain cells are harboring virus before the onset of HIVE. Our ability to detect HIV-1 DNA from specific brain cell types in a cohort of individuals who died from HIV-unrelated causes during presymptomatic infection presented a unique opportunity to identify cellular viral reservoirs of the brain. Our detection of HIV-1 gag DNA in long-lived brain cells without evidence of productive infection...
fection suggests that brain cell reservoirs of latent virus exist before HIV-1 onset. By the time of HIV-1, both perivascular macrophages and parenchymal microglia demonstrate productive HIV-1 infection in the brain, but astrocytes, which have been shown to contribute to neuropathogenesis, are not productively infected.

Parenchymal microglia are a stable, long-lived CNS cell population that form a dense network throughout the brain. Their anatomical location and morphology is distinct from that of perivascular macrophages. Latently infected parenchymal microglia in presymptomatic HIV-1 infection may well represent a constant CNS viral reservoir. Circulating blood monocytes traffic into the perivascular space to become tissue perivascular macrophages and are constantly turned over via the systemic circulation.

We previously examined brain cell-specific infection at multiple time points from acute to terminal infection in simian immunodeficiency virus (SIV) infected macaques. The study demonstrated that infected macrophages act as the Trojan horse within the brain perivascular space, with an initial increase in latent infection of perivascular macrophages and subsequent productive infection of perivascular macrophages and brain parenchymal cells concurrent with increasing plasma viral load and decreasing peripheral blood CD4 count. In our present study, we have similarly demonstrated increasing immunosuppression correlating with increasing latent HIV-1 infection of circulating perivascular macrophages before the onset of HIV-1. Both studies suggest that perivascular macrophages may be pivotal in advancing HIV-1 brain infection at times of increasing immunosuppression and that maintaining CD4 cell levels may be crucial for controlling a critical entry point of HIV-1 from the systemic circulation into the brain. It is yet to be determined whether the onset of HIV is due to reactivation of the microglial reservoir, influx of systemic HIV via infected macrophages, or both.

Our studies show microglial and astrocytic reactivity in the absence of HIV-1 p24 protein in brain tissue from presymptomatic individuals and that CD4 lymphocytic infiltration of the brain was negligible. Given latent virus detected within brain cells before HIV, this low-level activation of microglia and astrocytes may indicate a response to trafficking of HIV-1 into the brain and/or a change in the replication state of the latent infection.

CNS infiltration of activated monocytes/macrophages and microglial activation have been widely reported to be essential in the development of HIV-associated neurological disorders. A recent study showed that risk of HIV-associated neurological disorders is associated with nadir CD4 count.

Preventing CD4 decline by earlier initiation of combination antiretroviral therapy may reduce entry of HIV-1 infected perivascular macrophages from the systemic circulation into the brain and so reduce the likelihood of HIV-associated neurological disorders. In conclusion, we provide evidence that brain cell reservoirs of latent HIV-1 exist before the onset of pathological HIV and suggest that perivascular macrophages may be pivotal to brain disease progression at times of increasing immunosuppression. Therapies to prevent CNS HIV disease progression may thus need to target perivascular macrophages, before immunosuppression.

Acknowledgments
We thank Frances Carnie and the MRC HIV Brain and Tissue Bank (Edinburgh, UK) for providing samples and clinical information analyzed in this study. We also thank the staff of Anatomical Pathology, Alfred Hospital, for assistance with processing tissue samples.

References